Skip to main content

Radiotherapy is one of the main treatments for cancer and is used as an independent treatment or in combination with surgery and/or systemic treatment (i.e. chemotherapy). The goal is to cure cancer, to augment the prognosis, or to palliate symptoms.

Radiation therapy has a biological effect on the DNA and the inflammatory status of the tumor. The side effects are decreased by modern techniques that allow to paint the dose more precisely.

The proposed treatment is discussed with the patient at consultation, usually after multidisciplinary discussion. The radiation oncologist follows the patient throughout the radiotherapy treatment and takes part in the follow-up after therapy, in close collaboration with the other health professionals.

Research projects

Our dedicated research page provides a more comprehensive overview of our research activities. Below we show some examples of current research projects.

Projet 1

PEGASUS : Phase IIIb randomized trial comparing irradiation plus long-term adjuvant androgen deprivation with GnRH antagonist versus GnRH agonist plus flare protection in patients with very high risk localized or locally advanced prostate cancer. A joint study of the EORTC ROG and GUCG Pegasus
  • Project leader : Dr Otte
  • Promotor : EORTC
  • Funding: EORTC
  • Collaborations : Cliniques Universitaires Saint-Luc, UZ Brussel, Hopital De Jolimont

Projet 2

BEST OF : Phase III study assessing the “best of” radiotherapy compared to the “best of” surgery (trans-oral surgery (TOS)) in patients with T1-T2, N0-N1 oropharyngeal, supraglottic carcinoma and with T1, N0 hypopharyngeal carcinoma

Projet 3

SEMIRAHN : A prospective randomized phase 2 study of dose and volume de-escalation in prophylactic nodal irradiation of contralateral neck by sentinel lymph nodes mapping in unilaterally node positive head and neck squamous cell carcinomas.
  • Project leader : Pr Van Gestel
  • Promotor : UZ Leuven
  • Funding : Stichting tegen Kanker
  • Collaborations : CHU-UCL Namur, Universitaire Ziekenhuizen Leuven, University Hospital Gent

Projet 4

PART : Phase II Trial to Investigate the Benefit of Elective Para-Aortic Radiotherapy (PART) for pN1 Prostate Cancer Using Arc Therapy (IMAT/VMAT)
  • Project leader : Dr Otte
  • Promotor : UZ Leuven
  • Collaborations : UZ leuven

Projet 5

PRIMALUNG : PRophylactic cerebral Irradiation or active MAgnetic resonance imaging surveillance in small-cell Lung cancer patients (PRIMALung study)

projet 6

STEREOPAC: Preoperative treatment with mFOLFIRINOX or Gemcitabine/Nab-paclitaxel +/- isotoxic high-dose stereotactic body Radiation Therapy (iHD-SBRT) for borderline resectable pancreatic adenocarcinoma (the STEREOPAC trial)
  • Project leader : Dr Bouchart
  • Promotor : HUB
  • Funding : Anticancer Fund, Association Jules Bordet, Fonds de la Recherche Scientifique–FNRS, Fondation Roi Baudoin, Rising Tide 
  • Collaborations: Belgian Group of Digestive Oncology, University Hospital St Luc, Pôle Hospitalier Jolimont, UZA Antwerpen, CHIREC, AZ Groeninge, Clinique CHC Montlégia, CHU Ambroise Paré, UZ Gent

Projet 7

XRAY VISION: A randomized, double-blind, placebo-controlled, 2-arm Phase III study to assess efficacy and safety of xevinapant and radiotherapy compared to placebo and radiotherapy for demonstrating improvement of disease-free survival in participants with resected squamous cell carcinoma of the head and neck, who are at high risk for relapse and are ineligible for high-dose cisplatin

Projet 8

PROCAR-BQ: PROstate CAncer Radiotherapy: Its real impact on Bowel symptoms & Quality of Life today, measured by the EORTC QLQ C30 & specific PRT20 Module. PROstate CAncer Radiotherapy - Bowel Quality of Life (PROCAR-BQ)
  • Responsable : Dr De Bruyn
  • Promotor : HUB

Projet 9

SQUAL: A randomized phase II study to explore the benefits of the MonaLisa Touch® system in the improvement of the Sexual QUAlity of Life in gynaecological cancer patients treated by (chemo)-radiotherapy. 
  • Project leader : Dr Ahrouch
  • Promotor : HUB

Project 10

  • Project leader (Institut Bordet) : Sébastien Penninckx
  • Searcher : Eloïse Rapport
  • Funding : FNRS via appeal Télévie
  • Collaboration : Université de Namur (C. Michiels)

Project 11

  • Project leader (Institut Bordet): Sébastien Penninckx
  • Searchers : Nina Blond, Coralie Destrebecq, Ayoub Daraaoui
  • Funding : The "Association Jules Bordet", FNRS via appeals « Télévie » and « Aspirant »
  • Collaborations : IRIBHM (V. Wittamer, ULB)

Project 312

  • Project leadersNick Reynaert, Sébastien Penninckx
  • Searcher : Guillaume Houyoux
  • Funding: Région Wallonne via appeals « Biowin » and « MecaTech »
  • Collaboration: UC Louvain (E. Sterpin), IBA et Thélis


Our team

Head of Department
- Prof. MARTINIVE Philippe : neurological and digestive tumours

Medical Physics Department
The radiotherapy physics’ team is part of the central Medical Physics Department of the Institute.
Prof REYNAERT Nick, Head of Medical Physics Department:
Mr JOURANI Younes, Responsible for physics in radiotherapy:

Head of technologists
- GLINEUR Nicolas

Radiation Oncologists
- Dr AHROUCH Imane: breast and gynaecological tumours, brachytherapy
- Dr BOUCHART Christelle : pancreatic and neurological tumours
Dr COLLEN Christine : neurological and thoracic tumours
- Dr DESMET Antoine : breast and skin tumours, intraoperative radiotherapy and brachytherapy
- Dr DRAGAN Tatiana : head and neck tumours, sarcomas
- Prof. MORETTI Luigi : digestive and thoracic tumours
- Dr OTTE François-Xavier : urological tumours
- Dr PHILIPPSON Catherine : breast tumours and intraoperative radiotherapy
- Dr VAN DEN BEGIN Robbe : oligometastatic, urological and digestive tumours
- Dr VAN KAMPEN Daphné : breast tumours and lymphomas
- Prof. Honorary VAN HOUTTE Paul : thoracic and gynecological tumours, non-malignant tumours, brachytherapy
- Dr DE CALUWE Alex: Research consultant
- Prof. LAMBIN Philippe : Research Consultant
- Dr BARE Mathilde : brachytherapy
- Dr MANDERLIER Martin : brachytherapy
- Dr JULLIAN Nicolas : oligometastatic, urological and breast tumours

Radiation Oncologists in training
- BELLAL Sarah
- BOUSSADIA Badreddine
- DE BRUYN Pauline
- FARDEAU Emmanuel
- FISCH Maxim
- MICHEL Madeline
- NGUYEN Justin

Radiotherapy Nurse Coach
The Nurse Coach in radiotherapy supports the patients in organizing their multidisciplinary care, in the first place for the patients referred by other centers.
- HOUTEKENS Ysabelle
- BILLIET Maureen

Quality Manager
- KHAWAJA, Thérèse

- GEVART Elodie
- SEREDIUC Cristina
- DELVAEYE Valerie 


 Scientific publications

Radiation therapy-induced left vocal cord paralysis following lung stereotactic body radiation therapy: A case report and review of the literature.

Authors : Pierrard J, Deheneffe S, Longton E, Henry S, Van Houtte P, Remouchamps V
Year : 2023
Journal : Cancer Radiother
Volume : 27
Pages : 69-74

Cardiac safety of dual anti-HER2 blockade with pertuzumab plus trastuzumab in early HER2-positive breast cancer in the APHINITY trial.

Authors : de Azambuja E, Agostinetto E, Procter M, Eiger D, Pondé N, Guillaume S, Parlier D, Lambertini M, Desmet A, Caballero C, Aguila C, Jerusalem G, Walshe JM, Frank E, Bines J, Loibl S, Piccart-Gebhart M, Ewer MS, Dent S, Plummer C, Suter T
Year : 2023
Journal : ESMO Open
Volume : 8
Pages : 100772

Inter-fraction heart displacement during voluntary deep inspiration breath hold radiation therapy without visual feedback measured by daily CBCT.

Authors : Benkhaled S, Gomes da Silveira Cauduro C, Jullian N, Desmet A, Rodriguez D, Jourani Y, Van Gestel D, De Caluwé A
Year : 2022
Journal : Front Oncol
Volume : 12
Pages : 936088

The State of the Art of Radiotherapy for Non-melanoma Skin Cancer: A Review of the Literature.

Authors : Benkhaled S, Van Gestel D, Gomes da Silveira Cauduro C, Palumbo S, Del Marmol V, Desmet A
Year : 2022
Journal : Front Med (Lausanne)
Volume : 9
Pages : 913269

A nomogram to predict the recurrence-free survival and analyze the utility of chemotherapy in stage IB non-small cell lung cancer.

Authors : Zhang Z, Xie S, Cai W, Hong ZN, Yang C, Lin Y, Zhu J, Lin Z, Christoph DC, Bohnenberger H, Kepka L, Brueckl WM, Van Houtte P, Kang M, Lin J
Year : 2022
Journal : Transl Lung Cancer Res
Volume : 11
Pages : 75-86